Aller au contenu principal
Profil bibliographique

Sheena Cameron

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

9Publications signalées
2235Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 ResearchBone health and osteoporosis researchRespiratory Support and Mechanisms

Les publications récentes

Accès ouvert 2026 article OpenAlex

Relationships as Resistance

Sheena Cameron

At the core of the climate calamity is a clash in beliefs, values, knowledge, and actions affecting relationships between humans and the natural world. Although there is an urgent need for systems change, there is also a need to radically reimagine white …

ca (code pays fourni par la source)

0 citations Canadian Journal for the Study of Adult Education
Accès ouvert 2023 article OpenAlex

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Joshua Abbas et autres

BACKGROUND: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. …

gb (code pays fourni par la source)

132 citations The Lancet
Accès ouvert 2022 article OpenAlex

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, Ali Abbas, Fatima Abbas, Joshua Abbas et autres

BACKGROUND: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible …

gb (code pays fourni par la source)

335 citations The Lancet
Accès ouvert 2022 article OpenAlex

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

BACKGROUND: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab …

384 citations The Lancet
Accès ouvert 2021 article OpenAlex

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

BACKGROUND: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19. METHODS: In this randomised, controlled, open-label, platform trial, …

gb, id, np, vn (code pays fourni par la source)

292 citations The Lancet
Accès ouvert 2021 article OpenAlex

Moving with the Movements: Participatory Action Research in In/Action

Jonathan Langdon, Sheena Cameron, Natalie Krieger, A.B. Rami Shani

Participation by its very nature is iterative, meaning Participatory Action Research (PAR) must be responsive to the way participation manifests and what actions emerge from this participation. In the article that follows, we share the complex and intertwined stories of PAR in …

ca (code pays fourni par la source)

3 citations The Canadian Journal of Action Research
Accès ouvert 2021 article OpenAlex

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of …

gb, au (code pays fourni par la source)

524 citations The Lancet
Accès ouvert 2021 article OpenAlex

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, Alfie Abbott et autres

BACKGROUND: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. METHODS: In this randomised, controlled, open-label, adaptive platform …

au (code pays fourni par la source)

565 citations The Lancet

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.